BACKGROUND: We recently reported the association between the Malmö sequence variant in F9 (rs6048) and deep vein thrombosis. DESIGN AND METHODS: We aimed to study whether the association between F9 Malmö and deep vein thrombosis is explained by linkage disequilibrium with nearby single-nucleotide polymorphisms, and whether the association is explained biologically by F9 Malmö affecting factor IX antigen levels or activation of factor IX. We investigated the association of F9 Malmö and 28 nearby single-nucleotide polymorphisms with deep vein thrombosis in men from two case-control studies, LETS (n=380) and MEGA (n=1,469). We assessed the association of F9 Malmö with factor IX antigen level in male control subjects from LETS (n=191) and two subsets of MEGA (n=823 and n=484) and the association with endogenous thrombin potential in LETS control men. We studied the association between F9 Malmö and factor IX activation peptide in 1,199 healthy middle-aged men from the NPHS-II cohort. RESULTS: In the combined LETS and MEGA studies, the odds ratio (95% confidence interval) for the G allele of F9 Malmö, compared with the A allele, was 0.80 (0.69-0.93). One single-nucleotide polymorphism in F9, rs422187, was strongly linked to F9 Malmö (r(2)=0.94) and was similarly associated with deep vein thrombosis. No other single-nucleotide polymorphism or haplotype tested was more strongly associated. Factor IX antigen level, factor IX activation peptide levels and endogenous thrombin potential did not differ between F9 Malmö genotypes. CONCLUSIONS: The F9 Malmö sequence variant was the most strongly associated with deep vein thrombosis among common single-nucleotide polymorphisms in the region. However, the biological mechanism by which F9 Malmö affects risk remains unknown.
BACKGROUND: We recently reported the association between the Malmö sequence variant in F9 (rs6048) and deep vein thrombosis. DESIGN AND METHODS: We aimed to study whether the association between F9 Malmö and deep vein thrombosis is explained by linkage disequilibrium with nearby single-nucleotide polymorphisms, and whether the association is explained biologically by F9 Malmö affecting factor IX antigen levels or activation of factor IX. We investigated the association of F9 Malmö and 28 nearby single-nucleotide polymorphisms with deep vein thrombosis in men from two case-control studies, LETS (n=380) and MEGA (n=1,469). We assessed the association of F9 Malmö with factor IX antigen level in male control subjects from LETS (n=191) and two subsets of MEGA (n=823 and n=484) and the association with endogenous thrombin potential in LETS control men. We studied the association between F9 Malmö and factor IX activation peptide in 1,199 healthy middle-aged men from the NPHS-II cohort. RESULTS: In the combined LETS and MEGA studies, the odds ratio (95% confidence interval) for the G allele of F9 Malmö, compared with the A allele, was 0.80 (0.69-0.93). One single-nucleotide polymorphism in F9, rs422187, was strongly linked to F9 Malmö (r(2)=0.94) and was similarly associated with deep vein thrombosis. No other single-nucleotide polymorphism or haplotype tested was more strongly associated. Factor IX antigen level, factor IX activation peptide levels and endogenous thrombin potential did not differ between F9 Malmö genotypes. CONCLUSIONS: The F9 Malmö sequence variant was the most strongly associated with deep vein thrombosis among common single-nucleotide polymorphisms in the region. However, the biological mechanism by which F9 Malmö affects risk remains unknown.
Authors: J Rosing; G Tans; G A Nicolaes; M C Thomassen; R van Oerle; P M van der Ploeg; P Heijnen; K Hamulyak; H C Hemker Journal: Br J Haematol Date: 1997-04 Impact factor: 6.998
Authors: M Khachidze; A Buil; K R Viel; S Porter; D Warren; D K Machiah; J M Soria; J C Souto; A Ameri; M Lathrop; J Blangero; J Fontcuberta; S T Warren; L Almasy; T E Howard Journal: J Thromb Haemost Date: 2006-07 Impact factor: 5.824
Authors: Dov Shiffman; Charles M Rowland; Judy Z Louie; May M Luke; Lance A Bare; Joel I Bolonick; Bradford A Young; Joseph J Catanese; Charles F Stiggins; Clive R Pullinger; Eric J Topol; Mary J Malloy; John P Kane; Stephen G Ellis; James J Devlin Journal: Arterioscler Thromb Vasc Biol Date: 2006-05-11 Impact factor: 8.311
Authors: Rachel Kaiser; Yonghong Li; Monica Chang; Joseph Catanese; Ann B Begovich; Elizabeth E Brown; Jeffrey C Edberg; Gerald McGwin; Graciela S Alarcón; Rosalind Ramsey-Goldman; John D Reveille; Luis M Vilá; Michelle A Petri; Robert P Kimberly; Kimberly E Taylor; Lindsey A Criswell Journal: J Rheumatol Date: 2012-06-15 Impact factor: 4.666
Authors: Sara Lindström; Lu Wang; Erin N Smith; William Gordon; Astrid van Hylckama Vlieg; Mariza de Andrade; Jennifer A Brody; Jack W Pattee; Jeffrey Haessler; Ben M Brumpton; Daniel I Chasman; Pierre Suchon; Ming-Huei Chen; Constance Turman; Marine Germain; Kerri L Wiggins; James MacDonald; Sigrid K Braekkan; Sebastian M Armasu; Nathan Pankratz; Rebecca D Jackson; Jonas B Nielsen; Franco Giulianini; Marja K Puurunen; Manal Ibrahim; Susan R Heckbert; Scott M Damrauer; Pradeep Natarajan; Derek Klarin; Paul S de Vries; Maria Sabater-Lleal; Jennifer E Huffman; Theo K Bammler; Kelly A Frazer; Bryan M McCauley; Kent Taylor; James S Pankow; Alexander P Reiner; Maiken E Gabrielsen; Jean-François Deleuze; Chris J O'Donnell; Jihye Kim; Barbara McKnight; Peter Kraft; John-Bjarne Hansen; Frits R Rosendaal; John A Heit; Bruce M Psaty; Weihong Tang; Charles Kooperberg; Kristian Hveem; Paul M Ridker; Pierre-Emmanuel Morange; Andrew D Johnson; Christopher Kabrhel; David-Alexandre Trégouët; Nicholas L Smith Journal: Blood Date: 2019-11-07 Impact factor: 25.476
Authors: Mary Cushman; Joseph C Larson; Frits R Rosendaal; Susan R Heckbert; J David Curb; Lawrence S Phillips; Alison E Baird; Charles B Eaton; Randall S Stafford Journal: Res Pract Thromb Haemost Date: 2018-04-17